The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

RecruitingOBSERVATIONAL
Enrollment

784

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
GlioblastomaHigh-grade GliomaGlioblastoma, IDH-wildtypeGlioblastoma, IDH-mutantGlioblastoma Multiforme, AdultAstrocytoma, Grade IVAstrocytoma, Grade IIIAstrocytoma, MalignantBrain NeoplasmsBrain Neoplasm, PrimaryBrain Neoplasms, AdultBrain Neoplasm, Malignant
Interventions
PROCEDURE

Supramaximal resection

Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.

PROCEDURE

Maximal safe resection

Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.

Trial Locations (8)

3000

RECRUITING

University Hospitals Leuven, Leuven

3010

NOT_YET_RECRUITING

Inselspital Universitätsspital Bern, Bern

69120

RECRUITING

Universitätsklinikum Heidelberg, Heidelberg

74076

NOT_YET_RECRUITING

Technical University Munich, Munich

94143

RECRUITING

University of California, San Francisco (UCSF), San Francisco

02114

RECRUITING

Massachusetts General Hospital, Boston

3015 GD

RECRUITING

Erasmus Medical Center, Rotterdam

2512 VA

RECRUITING

Haaglanden Medical Centre, The Hague

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Haaglanden Medical Centre

OTHER

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

collaborator

University Hospital Heidelberg

OTHER

collaborator

Technical University of Munich

OTHER

collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of California, San Francisco

OTHER

lead

Jasper Gerritsen

OTHER